Boehringer Ingelheim and Enleofen partner to develop anti-IL-11 therapies for multiple fibrotic disorders

Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim’s leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company’s extensive range of therapeutic antibodies targeting this pathway.

Boehringer Ingelheim and Enleofen partner to develop anti-IL-11 therapies for multiple fibrotic disorders
Stuart Cook (Director & Co-Founder), Jeffery Lu (Director) and Andrew Khoo (Director)

The impressive preclinical studies at Enleofen have revealed the potential of IL-11 blockade to treat a broad range of diseases. We are excited to have these monoclonal antibodies in our pipeline and have the opportunity to accelerate their path to many patients whose needs are not met by current treatments.”

Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim

IL-11 is a cytokine, a protein certain cells of the body use to communicate, and plays a key role in fibro-inflammatory conditions. Blocking IL-11 action has been shown to inhibit disease across many organs (liver, lung, kidney, retina, bowel, heart and skin). In preclinical studies, antibody-based IL-11 antagonists were able to prevent and reverse inflammation and fibrosis, and restore organ function.

Enleofen is a spin out company from the National Heart Centre Singapore (NHCS) at SingHealth and Duke-NUS Medical School under the SingHealth Duke-NUS Academic Medical Centre (AMC), Singapore and exclusively licensed a suite of patents and number of antibody products when it was founded in 2017, from the AMC. Subsequent to this, Enleofen has built an extensive anti-IL-11 antibody platform and advanced its drug development programs towards the clinic. Boehringer Ingelheim will now develop this platform further and plans to work jointly with scientists at the AMC to accelerate the platform into clinical development. The initial focus will be on novel therapies for patients with NASH and ILDs, two of Boehringer Ingelheim’s core disease focus areas, with a potential to expand into further fibro-inflammatory conditions based on IL-11’s central role in disease.

Enleofen is very excited to engage Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D to develop further anti-IL-11 therapies to begin to address the unmet medical needs of patients worldwide. The preclinical data across a range of conditions are unprecedented and this new approach of targeting IL-11 could be a game changer”.

Prof Stuart Cook, Director and co-founder of Enleofen

The acquisition of the IL-11 program from Enleofen strengthens Boehringer Ingelheim’s pipeline portfolio, which combines approaches that are effective across multiple fibrotic diseases with disease-specific approaches to achieve greater therapeutic effect and builds on the experience gained with nintedanib in fibrotic lung diseases. Boehringer Ingelheim will be solely responsible for the clinical, regulatory and commercial development of the licensed therapies. Under the terms of the agreement, Enleofen may receive earn out payments in excess of one billion USD per product in upfront and success-based development and commercialization milestones.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Boehringer Ingelheim International GmbH. (2020, January 14). Boehringer Ingelheim and Enleofen partner to develop anti-IL-11 therapies for multiple fibrotic disorders. News-Medical. Retrieved on February 20, 2020 from https://www.news-medical.net/news/20200114/Boehringer-Ingelheim-and-Enleofen-partner-to-develop-anti-IL-11-therapies-for-multiple-fibrotic-disorders.aspx.

  • MLA

    Boehringer Ingelheim International GmbH. "Boehringer Ingelheim and Enleofen partner to develop anti-IL-11 therapies for multiple fibrotic disorders". News-Medical. 20 February 2020. <https://www.news-medical.net/news/20200114/Boehringer-Ingelheim-and-Enleofen-partner-to-develop-anti-IL-11-therapies-for-multiple-fibrotic-disorders.aspx>.

  • Chicago

    Boehringer Ingelheim International GmbH. "Boehringer Ingelheim and Enleofen partner to develop anti-IL-11 therapies for multiple fibrotic disorders". News-Medical. https://www.news-medical.net/news/20200114/Boehringer-Ingelheim-and-Enleofen-partner-to-develop-anti-IL-11-therapies-for-multiple-fibrotic-disorders.aspx. (accessed February 20, 2020).

  • Harvard

    Boehringer Ingelheim International GmbH. 2020. Boehringer Ingelheim and Enleofen partner to develop anti-IL-11 therapies for multiple fibrotic disorders. News-Medical, viewed 20 February 2020, https://www.news-medical.net/news/20200114/Boehringer-Ingelheim-and-Enleofen-partner-to-develop-anti-IL-11-therapies-for-multiple-fibrotic-disorders.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.